Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer after Resection (ARTEMIDE-Biliary01)

Trial Identifier: D7025C00001
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: June 2029
Study Completion Date: September 2030
Condition: Liver Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations